Total Payments
$36,718
2024 Payments
$5,059
Companies
84
Transactions
1,200
Medicare Patients
8,499
Medicare Billing
$2.8M
Payment Breakdown by Category
Food & Beverage$21,876 (59.6%)
Consulting$9,785 (26.6%)
Other$4,924 (13.4%)
Education$132.71 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $21,876 | 1,178 | 59.6% |
| Consulting Fee | $9,785 | 4 | 26.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,375 | 2 | 11.9% |
| Long term medical supply or device loan | $549.09 | 6 | 1.5% |
| Education | $132.71 | 10 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $6,227 | 126 | $0 (2024) |
| ABBVIE INC. | $4,455 | 22 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $4,421 | 95 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $3,223 | 37 | $0 (2024) |
| Celgene Corporation | $1,994 | 68 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,722 | 108 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,302 | 106 | $0 (2024) |
| Genentech USA, Inc. | $993.55 | 59 | $0 (2024) |
| Amgen Inc. | $924.09 | 46 | $0 (2023) |
| Janssen Biotech, Inc. | $783.27 | 42 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,059 | 213 | PFIZER INC. ($424.81) |
| 2023 | $7,621 | 210 | AstraZeneca Pharmaceuticals LP ($2,661) |
| 2022 | $4,070 | 215 | Novartis Pharmaceuticals Corporation ($511.35) |
| 2021 | $6,492 | 119 | AbbVie Inc. ($4,116) |
| 2020 | $2,862 | 23 | Novartis Pharmaceuticals Corporation ($2,475) |
| 2019 | $4,665 | 141 | PFIZER INC. ($2,912) |
| 2018 | $1,926 | 156 | Merck Sharp & Dohme Corporation ($215.97) |
| 2017 | $4,023 | 123 | PFIZER INC. ($1,887) |
All Payment Transactions
1,200 individual payment records from CMS Open Payments — Page 1 of 48
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $24.17 | General |
| Category: Oncology | ||||||
| 12/17/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $8.67 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.02 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $9.65 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $13.05 | General |
| Category: Oncology | ||||||
| 12/10/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Food and Beverage | In-kind items and services | $22.98 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $18.61 | General |
| Category: Hematology | ||||||
| 12/06/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $20.98 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $6.50 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $20.10 | General |
| Category: Hematology | ||||||
| 12/05/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $18.46 | General |
| Category: Hematology/Oncology | ||||||
| 12/04/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $32.60 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | SERVIER PHARMACEUTICALS LLC | — | Food and Beverage | In-kind items and services | $23.10 | General |
| 12/03/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $13.95 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $13.34 | General |
| Category: Oncology | ||||||
| 12/02/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $21.46 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $20.60 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $24.37 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: Oncology | ||||||
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $23.15 | General |
| 11/12/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $25.06 | General |
| Category: Oncology / Rare Diseases | ||||||
| 11/06/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Incyte Corporation | PEMAZYRE (Drug), MONJUVI | Food and Beverage | Cash or cash equivalent | $26.95 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 11/05/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $22.75 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $26.46 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 43 | 2,029 | 65,182 | $4.1M | $1.1M |
| 2022 | 50 | 2,399 | 86,733 | $3.6M | $940,167 |
| 2021 | 36 | 1,786 | 36,945 | $1.2M | $405,504 |
| 2020 | 39 | 2,285 | 35,434 | $2.0M | $450,116 |
Total Patients
8,499
Total Services
224,294
Medicare Billing
$2.8M
Procedure Codes
168
All Medicare Procedures & Services
168 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 13 | 13,600 | $2.1M | $585,140 | 27.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 42 | 9,120 | $583,680 | $167,795 | 28.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 343 | 857 | $237,666 | $54,858 | 23.1% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 14 | 6,490 | $162,250 | $38,912 | 24.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 159 | 398 | $155,220 | $36,991 | 23.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 58 | 340 | $143,140 | $33,096 | 23.1% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 12 | 1,400 | $103,600 | $23,218 | 22.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 104 | 104 | $69,992 | $16,388 | 23.4% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 15 | 8,450 | $50,700 | $11,578 | 22.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 438 | 1,513 | $43,877 | $11,495 | 26.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 68 | 447 | $46,041 | $9,441 | 20.5% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 13 | 69 | $41,607 | $9,132 | 21.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 52 | 161 | $33,488 | $7,574 | 22.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 43 | 55 | $30,250 | $7,102 | 23.5% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 17 | 16,320 | $65,280 | $6,708 | 10.3% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 21 | 68 | $14,280 | $4,900 | 34.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 84 | 353 | $23,651 | $3,619 | 15.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 17 | 70 | $14,350 | $3,390 | 23.6% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 16 | 69 | $12,213 | $2,876 | 23.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 18 | 18 | $10,710 | $2,334 | 21.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $9,162 | $2,297 | 25.1% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 18 | 77 | $12,628 | $1,622 | 12.8% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 16 | 60 | $8,100 | $1,506 | 18.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 16 | $4,928 | $1,470 | 29.8% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 15 | 25 | $7,825 | $1,383 | 17.7% |
About Dr. Tania Cortas, MD
Dr. Tania Cortas, MD is a Medical Oncology healthcare provider based in Phoenix, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/13/2007. The National Provider Identifier (NPI) number assigned to this provider is 1720293608.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tania Cortas, MD has received a total of $36,718 in payments from pharmaceutical and medical device companies, with $5,059 received in 2024. These payments were reported across 1,200 transactions from 84 companies. The most common payment nature is "Food and Beverage" ($21,876).
As a Medicare-enrolled provider, Cortas has provided services to 8,499 Medicare beneficiaries, totaling 224,294 services with total Medicare billing of $2.8M. Data is available for 4 years (2020–2023), covering 168 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Phoenix, AZ
- Active Since 05/13/2007
- Last Updated 09/11/2023
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1720293608
Products in Payments
- IBRANCE (Drug) $5,003
- VENCLEXTA (Drug) $4,286
- IMFINZI (Biological) $2,594
- KEYTRUDA (Biological) $1,646
- OPDIVO (Biological) $968.62
- Abraxane (Drug) $831.24
- Lenvima (Drug) $595.32
- CABOMETYX (Drug) $592.60
- KISQALI (Drug) $557.28
- REBLOZYL (Biological) $466.83
- VERZENIO (Drug) $445.64
- Enhertu (Drug) $368.13
- Pomalyst (Drug) $345.33
- XTANDI (Drug) $331.18
- XPOVIO (Drug) $315.21
- IMBRUVICA (Drug) $285.96
- JEVTANA (Drug) $259.17
- Alecensa (Biological) $255.14
- Kyprolis (Drug) $248.44
- INJECTAFER (Drug) $246.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Phoenix
Dr. Jason Salganick, Md, MD
Medical Oncology — Payments: $1.9M
Medical Oncology $1.9M
Mazen Khattab, Md, MD
Medical Oncology — Payments: $226,385
Medical Oncology $226,385
Panayiotis Savvides, Md, MD
Medical Oncology — Payments: $217,105
Medical Oncology $217,105
Amber Flaherty, M.d, M.D
Medical Oncology — Payments: $41,476
Medical Oncology $41,476
Waqas Arslan, M.d, M.D
Medical Oncology — Payments: $34,523
Medical Oncology $34,523
Dr. Amir Azadi, M.d, M.D
Medical Oncology — Payments: $23,762
Medical Oncology $23,762